Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer
暂无分享,去创建一个
L. Paz-Ares | S. Molina-Pinelo | Luis Paz-Ares | I. Ferrer | Ángela Marrugal | Laura Ojeda | Sonia Molina-Pinelo | Irene Ferrer | Á. Marrugal | Laura Ojeda
[1] Ji-shuai Zhang,et al. Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer , 2013, PloS one.
[2] N. Rothman,et al. Intra-individual variability over time in serum cytokine levels among participants in the prostate, lung, colorectal, and ovarian cancer screening Trial. , 2011, Cytokine.
[3] T. Bayer,et al. Protein signature for non-small cell lung cancer prognosis. , 2014, American journal of cancer research.
[4] C. Roussos,et al. VEGF and IL-18 in induced sputum of lung cancer patients. , 2011, Cytokine.
[5] J. Lehtiö,et al. Lung cancer proteomics, clinical and technological considerations. , 2010, Journal of proteomics.
[6] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[7] D. Messmer,et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC) , 2011, Journal of Cancer Research and Clinical Oncology.
[8] Jiayou Zhang,et al. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. , 2010, Cytokine.
[9] E. Bargagli,et al. Proteome analysis of bronchoalveolar lavage in lung diseases , 2006, Proteomics.
[10] D. Waugh,et al. The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.
[11] M. Selbach,et al. SILAC for biomarker discovery , 2015, Proteomics. Clinical applications.
[12] Yun Chen,et al. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis , 2016, Oncotarget.
[13] D. Hicklin,et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] T. Veikkola,et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.
[15] C. Drake,et al. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.
[16] Shao-En Ong. The expanding field of SILAC , 2012, Analytical and Bioanalytical Chemistry.
[17] L. Raez,et al. Active immunotherapy for non-small-cell lung cancer: moving toward a reality , 2011, Expert review of anticancer therapy.
[18] W. Guo,et al. Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review and meta-analysis. , 2014, Cancer biomarkers : section A of Disease markers.
[19] J. Machiels,et al. A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors , 2014, Clinical Cancer Research.
[20] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[21] P. Chaurand,et al. Mass spectrometry-based proteomic profiling of lung cancer. , 2009, Proceedings of the American Thoracic Society.
[22] Matthias Mann,et al. Fifteen years of Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC). , 2014, Methods in molecular biology.
[23] Li-hua Shang,et al. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer , 2015, Scientific Reports.
[24] T. Lan,et al. Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.
[25] S. Takanashi,et al. Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. , 2005, Internal medicine.
[26] Baoan Chen,et al. Siltuximab (CNTO 328): a promising option for human malignancies , 2015, Drug design, development and therapy.
[27] E. Venkatraman,et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. , 2006, Chest.
[28] T. Mekhail,et al. Interleukin-2 in Cancer Therapy , 2000, BioDrugs.
[29] T. Geiger,et al. Super-SILAC: current trends and future perspectives , 2015, Expert review of proteomics.
[30] Hua Yu,et al. IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway , 2009, The Journal of experimental medicine.
[31] Wan-ying Wu,et al. Possible target‐related proteins and signal network of bufalin in A549 cells suggested by both iTRAQ‐based and label‐free proteomic analysis , 2016, Proteomics.
[32] Y. Horiguchi,et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] T. Poussa,et al. Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. , 2010, Cytokine.
[34] C. Libert,et al. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation , 2007, Journal of leukocyte biology.
[35] E. Garon. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. , 2015, Seminars in oncology.
[36] G. Murray,et al. The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis , 2011, PloS one.
[37] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[38] Ruo-Pan Huang,et al. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.
[39] N. Altorki,et al. The Microenvironment of Lung Cancer and Therapeutic Implications. , 2016, Advances in experimental medicine and biology.
[40] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[41] K. Kiura,et al. Induction of TNF-α, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells , 2003, Cancer Chemotherapy and Pharmacology.
[42] L. Paz-Ares,et al. Proteomic biomarkers in lung cancer , 2013, Clinical and Translational Oncology.
[43] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[44] V. Ganju,et al. The Evolution of Therapies in Non-Small Cell Lung Cancer , 2015, Cancers.
[45] W. Gerald,et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.
[46] Ruo-Pan Huang. Cytokine protein arrays. , 2004, Methods in molecular biology.
[47] M. Karamouzis,et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.
[48] G. Catalano,et al. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival , 2000, Cancer Immunology, Immunotherapy.
[49] J. Barbuto,et al. Functional analysis of cells obtained from bronchoalveolar lavage fluid (BALF) of lung cancer patients. , 2005, Life sciences.
[50] Wan-Wan Lin,et al. A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.
[51] Meta-analysis of association between cytokine gene polymorphisms and lung cancer risk , 2012, Molecular Biology Reports.
[52] G. Strauss,et al. Use of tumor markers in lung cancer. , 1994, Hematology/oncology clinics of North America.
[53] R. Abe,et al. Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model , 2016, Cancer Immunology, Immunotherapy.
[54] N. Mukaida,et al. Chemokines in tumor development and progression. , 2012, Experimental cell research.
[55] Ewa Wójcik,et al. Pretreatment Serum Levels of Cytokines and Cytokine Receptors in Patients with Non-Small Cell Lung Cancer, and Correlations with Clinicopathological Features and Prognosis , 2006, Oncology.
[56] J. Reichert. Antibodies to watch in 2016 , 2016, mAbs.
[57] J. Tabarkiewicz,et al. Surgery decreases number of cells secreting cytotoxic mediators and increases secretion of interleukin 10 in patients with lung cancer. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[58] C. Blank,et al. Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection1 , 2006, The Journal of Immunology.
[59] D. Porteous,et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. , 2008, American journal of respiratory and critical care medicine.
[60] S. Land,et al. Cytokine and Cytokine Receptor Single-Nucleotide Polymorphisms Predict Risk for Non–Small Cell Lung Cancer among Women , 2009, Cancer Epidemiology Biomarkers & Prevention.
[61] E. van Marck,et al. Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer , 2003, International journal of cancer.
[62] M. Smyth,et al. Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.
[63] H. Joensuu,et al. High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer , 1998, International journal of cancer.
[64] J. Nakajima,et al. γδ T cell therapy for the treatment of non-small cell lung cancer. , 2014, Translational lung cancer research.
[65] N. Senzer,et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] Ying E Zhang,et al. Non-Smad pathways in TGF-β signaling , 2009, Cell Research.
[67] Wen-Wei Hu,et al. Tumor-associated macrophages in cancers , 2016, Clinical and Translational Oncology.
[68] G. Mantovani,et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites , 2000, Journal of Molecular Medicine.
[69] Shu-hong Sheng,et al. Proteomic analysis of pleural effusion from lung adenocarcinoma patients by shotgun strategy , 2014, Clinical and Translational Oncology.
[70] P. Indovina,et al. Lung Cancer Proteomics: Recent Advances in Biomarker Discovery , 2011, International journal of proteomics.
[71] S. Weitzman,et al. Chronic inflammation and cancer. , 2002, Oncology.
[72] Lon Smith,et al. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.
[73] H. Groen,et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. , 1994, Blood.
[74] Lei Zhang,et al. Proteomic Analysis of Human Saliva From Lung Cancer Patients Using Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.
[75] A. Tarhini,et al. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. , 2015, Seminars in oncology.
[76] G. Giaccone,et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. , 2015, European journal of cancer.
[77] M. Tagawa,et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer , 2004, Cancer Immunology, Immunotherapy.
[78] C. Harris,et al. Radical causes of cancer , 2003, Nature Reviews Cancer.
[79] E. Szabo,et al. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research. , 2009, Journal of the National Cancer Institute.
[80] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[81] E. Felip,et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. , 2016, The Lancet. Oncology.
[82] R. Sun,et al. Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts , 2008, Clinical Cancer Research.
[83] Ho-June Lee,et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. , 2014, Cancer cell.
[84] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[85] Lixia Huang,et al. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. , 2014, Cytokine.
[86] T. Mak,et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies , 2009, Nature Medicine.
[87] R. Ramlau,et al. A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[88] Melissa H Wong,et al. Tumor microenvironment complexity: emerging roles in cancer therapy. , 2012, Cancer research.
[89] Jun-Xia Cao,et al. Adoptive Immunotherapy of Cytokine-Induced Killer Cell Therapy in the Treatment of Non-Small Cell Lung Cancer , 2014, PloS one.
[90] P. Woll,et al. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells , 2004, British Journal of Cancer.
[91] David Elashoff,et al. Development of transcriptomic biomarker signature in human saliva to detect lung cancer , 2012, Cellular and Molecular Life Sciences.
[92] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[93] T. Mak,et al. Fighting cancers from within: augmenting tumor immunity with cytokine therapy. , 2010, Trends in pharmacological sciences.
[94] Wei-Chih Liao,et al. Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma , 2008, Clinical Cancer Research.
[95] Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy , 2015, Pharmacotherapy.
[96] Wei Wang,et al. Serum Angiopoietin-2 as a Clinical Marker for Lung Cancer in Patients with Solitary Pulmonary Nodules. , 2016, Annals of Clinical and Laboratory Science.
[97] T. Blankenstein. The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.
[98] M. Buyse,et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. , 2011, The Lancet. Oncology.
[99] Haiquan Chen,et al. Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between Overexpressed Serum Proteins and Non-Small Cell Lung Cancer , 2012, PloS one.
[100] L. Paz-Ares,et al. Identification of proteomic signatures associated with lung cancer and COPD. , 2013, Journal of proteomics.
[101] Yan Chen,et al. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer , 2016, Journal of Experimental & Clinical Cancer Research.
[102] Shizuo Akira,et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.
[103] J. Limacher,et al. TG4010: A therapeutic vaccine against MUC1 expressing tumors. , 2012, Oncoimmunology.
[104] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[105] B. Palmer,et al. Interleukin 37 is a fundamental inhibitor of innate immunity , 2010, Nature Immunology.
[106] Yoshimasa Tanaka,et al. γδ T Cell Immunotherapy—A Review , 2015, Pharmaceuticals.
[107] Peiliang Geng,et al. Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer. , 2015, International journal of clinical and experimental medicine.
[108] W. Warren,et al. Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma , 2000, Cancer Immunology, Immunotherapy.
[109] Yanju Ma,et al. Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors , 2015, International journal of molecular medicine.
[110] K. Kikuchi,et al. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. , 2004, Lung cancer.
[111] X. Zhong,et al. The Treg/Th17 Paradigm in Lung Cancer , 2014, Journal of immunology research.
[112] J. Ferlay,et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. , 2014, Lung cancer.
[113] Elise C. Kohn,et al. Proteomics as a Tool for Biomarker Discovery , 2007, Disease markers.
[114] Stefani N. Thomas,et al. Advances in mass spectrometry-based clinical biomarker discovery , 2016, Clinical Proteomics.
[115] G. Giamas,et al. Strategies in functional proteomics: Unveiling the pathways to precision oncology. , 2016, Cancer letters.
[116] N. Songür,et al. Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Tumori.
[117] Shasha Wei,et al. Quantitative proteomics using SILAC: Principles, applications, and developments , 2015, Proteomics.
[118] P. Diot,et al. Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis , 2016, European Respiratory Journal.
[119] A. Nicolini,et al. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy. , 2007, Cancer letters.
[120] C. McDonald,et al. Quantitative proteomics of bronchoalveolar lavage fluid in lung adenocarcinoma. , 2015, Cancer genomics & proteomics.
[121] M. Shibuya,et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.
[122] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[123] F. Tas,et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. , 2008, Lung cancer.
[124] G. Fei,et al. A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer , 2015, OncoTargets and therapy.
[125] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[126] Putty-Reddy Sudhir,et al. Proteomics-Based Analysis of Protein Complexes in Pluripotent Stem Cells and Cancer Biology , 2016, International journal of molecular sciences.
[127] Chien-Jen Chen,et al. Circulating interleukin‐6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy , 2013, International journal of cancer.
[128] M. Moran,et al. Proteomic profiles of human lung adeno and squamous cell carcinoma using super‐SILAC and label‐free quantification approaches , 2014, Proteomics.
[129] R. Sallam. Proteomics in Cancer Biomarkers Discovery: Challenges and Applications , 2015, Disease markers.
[130] G. Vartholomatos,et al. Cytokine effects on cell survival and death of A549 lung carcinoma cells. , 2013, Cytokine.
[131] K. O'Byrne,et al. The role of inflammation in the pathogenesis of non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[132] K. Jain. Role of Proteomics in the Development of Personalized Medicine. , 2016, Advances in protein chemistry and structural biology.
[133] R. Catarino,et al. IL-6 polymorphism in non-small cell lung cancer: a prognostic value? , 2015, Tumor Biology.
[134] Tetsuro Baba,et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro , 2007, Cancer science.
[135] G. Elmberger,et al. A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants , 2010, Proteome Science.
[136] M. Masuda,et al. Proteomic approaches to the discovery of cancer biomarkers for early detection and personalized medicine. , 2013, Japanese journal of clinical oncology.
[137] Helen H. W. Chen,et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion , 2006, Oncogene.
[138] Leah E. Mechanic,et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. , 2011, Journal of the National Cancer Institute.
[139] F. Santolaria,et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. , 1999, Cytokine.
[140] C. Wingren,et al. Antibody array generation and use. , 2014, Methods in molecular biology.
[141] Hye-Jin Sung,et al. Biomarkers for the lung cancer diagnosis and their advances in proteomics. , 2008, BMB reports.